Market Overview

UPDATE: Jefferies Downgrades Ventas to Hold on Valuation and Post-Acute Concerns

Share:
Related VTR
Build A Basket Of 'Pure Play' Healthcare REITs...Or Just One Blue Chip?
Ventas Shares Are Sharply Lower: Why Shareholders Should Be Pleased
My 4% Dividend Yield Portfolio: Or Is It 5% Now? (Seeking Alpha)

Jefferies reduced its rating on Ventas (NYSE: VTR) from Buy to Hold but raised its price target from $65 to $66.

Jefferies noted, "Downgrading VTR to Hold on post-acute care concerns and valuation: Healthcare REITs with meaningful exposure to LTACs and IRFs include Medical Property Trust (MPW, Hold, $11.61) and Ventas (VTR, Hold, $64.51). At MPW, it is 43% of the asset base, and at VTR, we estimate it is 5% to 8% of net operating income (NOI). We are downgrading VTR to a Hold rating from our prior Buy rating given this concern. As valuation appears full at 16.4x P/FFO and a 5.3% implied cap rate, we believe the risk/reward with VTR stock is now balanced, rather than being favorable."

Ventas closed at $64.51 on Monday.

Latest Ratings for VTR

DateFirmActionFromTo
Aug 2015CitigroupMaintainsNeutral
Aug 2015BMO CapitalMaintainsOutperform
Aug 2015CitigroupMaintainsNeutral

View More Analyst Ratings for VTR
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (VTR)

Get Benzinga's Newsletters